Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1206 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

Year : 2003  |  Volume : 14  |  Issue : 4  |  Page : 492-496
The Clinical Significance of β2-microglobulin in End-Stage Renal Disease

1 Department of Nephrology and Dialysis, Rasheed Center of Postgraduate Medical Teaching, Rasheed Hospital, Baghdad, Iraq
2 Department of Immunology, Rasheed Center of Postgraduate Medical Teaching, Rasheed Hospital, Baghdad, Iraq
3 Department of Nephrology, Rasheed Center of Postgraduate Medical Teaching, Rasheed Hospital, Baghdad, Iraq

Correspondence Address:
Iqdam K Al-Taee
Rasheed Hospital, P.O. Box 3712, Alwiya, Baghdad
Login to access the Email id

PMID: 17657122

Rights and Permissions

β2-microglobulin is a non glycosylated single chain protein present in light chain of HLA-class I. It is synthesized in the body and excreted in the urine. Its level increases in the blood of the chronic renal failure patients and may deposit in the soft tissue as β2-microglobulin derived amyloidosis, which appear clinically after 5 years of dialysis. We studied 64 patients (49(76%) men) with end stage renal disease (ESRD) on regular hemodialysis. The mean age was 34.3 12 years and the duration of dialysis ranged between 0.4-12 years. Twenty-five healthy persons with mean age 34 17.6 years were used as a control group. The blood level of β2-M in the control group ranged from 0.73-3.81 mg/l, while the range in the study group was 5.2-51.8 mg/l. In the urine of the control group, β2-M level ranged from 0-0.7 mg/l, while in the control group it ranged from 0.07-11.8 mg/l. There was significant difference in the β2-M level in both control and study groups. A direct correlation was found between the duration of dialysis and the level of β2-M in the blood. The traditional low flux dialyzer membrane had no effects on β2-M level in our series. We conclude that there is increased tendency with time for retention of β2-M in the ESRD patients on chronic dialysis. Using dialyzers with high flux synthetic membrane (e.g. acrylonitrile, polyamide, and polysulphone) rather than the low flux membrane may allow substantial removal of β2-M molecules, especially in patients who have little chance of receiving renal transplantation.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded832    
    Comments [Add]    

Recommend this journal